What are alternative therapies to statins for lowering LDL cholesterol in patients who cannot tolerate statins?

Alternative to Statins for LDL Cholesterol Lowering

For patients who cannot tolerate statins, ezetimibe should be the first-line alternative therapy, followed by PCSK9 inhibitors (evolocumab or alirocumab) if additional LDL-C lowering is needed, with bempedoic acid as another option particularly for those unable to use injectables. 1

Algorithmic Approach to Statin Alternatives

Step 1: Initial Alternative Therapy

• Start with ezetimibe 10 mg daily as the first nonstatin agent 1
  • Provides approximately 18-25% LDL-C reduction 1
  • Excellent safety profile with no muscle-related adverse effects 2
  • Oral administration, once daily
  • Well-tolerated with minimal drug interactions 2

Step 2: If Ezetimibe Alone Is Insufficient

Add or switch to PCSK9 monoclonal antibodies if LDL-C targets are not met 1, 3:

• Evolocumab or alirocumab are preferred as they have proven cardiovascular outcomes benefits from FOURIER and ODYSSEY Outcomes trials 1
• PCSK9 inhibitors reduce LDL-C by approximately 36-37% more than ezetimibe alone in statin-intolerant patients 4
• Combination of evolocumab plus ezetimibe provides the greatest LDL-C reduction (approximately 49% reduction vs ezetimibe alone) and ranks highest in comparative effectiveness 3

Step 3: Alternative Options

Bempedoic acid can be considered as an alternative, particularly for:

• Patients who cannot self-inject or refuse injectable therapies 1
• Statin-intolerant patients, as it provides liver-selective cholesterol synthesis inhibition without muscle-related adverse effects 2
• CLEAR Outcomes trial demonstrated cardiovascular event reduction in statin-intolerant populations 5

Inclisiran may be considered for:

• Patients with demonstrated poor adherence to PCSK9 mAbs 1
• Those unable to self-inject (requires only twice-yearly dosing after loading) 1
• Note: Currently no cardiovascular outcomes data available 1

Key Safety Considerations

Ezetimibe

• Contraindicated only in hypersensitivity 1
• Monitor hepatic transaminases if combined with any statin therapy 1
• Not recommended in moderate/severe hepatic impairment 1

PCSK9 Inhibitors

• Minimal adverse effects beyond mild injection site reactions 2
• No muscle symptoms, no increased diabetes risk 2
• No major drug interactions 2

Bempedoic Acid

• Small increase in plasma uric acid 2
• Slightly increased frequency of gout episodes in susceptible patients 2
• Otherwise excellent safety profile without muscle symptoms 2

Common Pitfalls to Avoid

1. Don't delay adding nonstatin therapy in high-risk patients who cannot tolerate statins—these patients remain at significant cardiovascular risk
2. Don't use inclisiran as first-line PCSK9 inhibitor when evolocumab or alirocumab are available, as the latter have proven cardiovascular outcomes 1
3. Don't combine PCSK9 mAb with inclisiran—no evidence for additional benefit; use one or the other 1
4. Don't forget to refer patients with baseline LDL-C ≥190 mg/dL or intolerance to multiple statins to a lipid specialist 1

LDL-C Targets for Statin-Intolerant Patients

The same aggressive targets apply as for statin-treated patients 1, 6:

• Very high-risk ASCVD: ≥50% LDL-C reduction AND LDL-C <55 mg/dL (or non-HDL-C <85 mg/dL)
• High-risk ASCVD: ≥50% LDL-C reduction AND LDL-C <70 mg/dL (or non-HDL-C <100 mg/dL)
• Primary prevention with LDL-C ≥190 mg/dL: LDL-C <100 mg/dL

Practical Implementation

Cost and access remain significant barriers 5. PCSK9 inhibitors require prior authorization in most systems, and uninsured patients face prohibitive costs without assistance programs 5. Ezetimibe is generally more accessible and affordable, making it the logical first step 1.

For patients requiring maximal LDL-C reduction (very high-risk ASCVD), consider simultaneous addition of ezetimibe plus PCSK9 mAb rather than sequential therapy to reduce recurrent events more rapidly 1.